D.E. Shaw & Co
ANIK icon

D.E. Shaw & Co’s Anika Therapeutics ANIK Stock Holding History

D.E. Shaw & Co’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,900
Closed -$366K – 4079
2014
Q2 		$366K Sell
7,900
-41,100
-84% -$1.83M ﹤0.01% 3731
2014
Q1 		$2.01M Buy
49,000
+21,300
+77% +$792K ﹤0.01% 2387
2013
Q4 		$1.06M Buy
+27,700
New +$855K ﹤0.01% 3126

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co's ANIK Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Anika Therapeutics (ANIK) stake by 23% in Q1 2026, selling an estimated $791K and leaving 229,796 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

D.E. Shaw & Co first reported a position in ANIK in Q2 2013 and has held it in 46 quarters since. The position peaked at $22.4M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • D.E. Shaw & Co held 229,796 shares of Anika Therapeutics worth $3.33M as of Q1 2026.
  • D.E. Shaw & Co sold 68,183 Anika Therapeutics shares in Q1 2026, an estimated $791K.
  • Anika Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2497 holding.
  • D.E. Shaw & Co first reported a position in Anika Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • D.E. Shaw & Co's Anika Therapeutics position peaked at $22.4M in Q3 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.